RSLS - ReShape Lifesciences Inc.
NASDAQ
->
Healthcare
->
Medical Devices
San Clemente,
United States
Type: Equity
RSLS price evolution
RSLS
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.66 | $2.2 | $1.98 | $2.13 |
| Inventory | $3.74 | $3.2 | $3.27 | $3.49 |
| Total current assets | $10.3 | $7.4 | $10.54 | $15.23 |
| Long term investments | ||||
| Property, plant & equipment | $0.31 | $0.3 | $0.96 | $0.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $10.66 | $7.8 | $11.85 | $16.35 |
| Current liabilities | ||||
| Accounts payable | $1.69 | $1.5 | $1.6 | $2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.78 | $4.5 | $4.4 | $7.6 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4 | $4.7 | $5.11 | $8.59 |
| Shareholders' equity | ||||
| Retained earnings | -$635.57 | -$633.9 | -$630.34 | -$626.85 |
| Other shareholder equity | -$0.09 | -$0.1 | -$0.1 | -$0.09 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.9 | |||
| Short term investments | ||||
| Net receivables | $1.66 | $2.18 | $2.81 | $2.62 |
| Inventory | $3.74 | $3.61 | $3 | $2.24 |
| Total current assets | $10.3 | $9.91 | $30.25 | $7.83 |
| Long term investments | ||||
| Property, plant & equipment | $0.31 | $0.87 | $1.72 | $0.96 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.78 | |||
| Total investments | ||||
| Total assets | $10.66 | $11.14 | $54.26 | $10.62 |
| Current liabilities | ||||
| Accounts payable | $1.69 | $1.93 | $3.47 | $0.61 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.78 | $7.48 | $7.33 | $5.05 |
| Long term debt | $0.43 | |||
| Total noncurrent liabilities | $0.91 | |||
| Total debt | ||||
| Total liabilities | $4 | $7.48 | $8.19 | $5.95 |
| Shareholders' equity | ||||
| Retained earnings | -$635.57 | -$624.19 | -$576.76 | -$184.76 |
| Other shareholder equity | -$0.09 | -$0.09 | -$0.09 | -$0.12 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.98 | $2.29 | ||
| Cost of revenue | ||||
| Gross Profit | $1.84 | $1.22 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.74 | $6.86 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.03 | $0.01 | ||
| Interest expense | $0.11 | $2.98 | ||
| Net income | ||||
| Net income | -$1.7 | -$2.66 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.68 | $13.6 | $1.59 | |
| Cost of revenue | ||||
| Gross Profit | $5.55 | $8.35 | $0.58 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.19 | $33.8 | $11.23 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.05 | -$0.11 | ||
| Interest expense | $3.93 | -$0.66 | $0.03 | |
| Net income | ||||
| Net income | -$11.39 | -$61.93 | -$12.33 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $17.57 | $12.11 | $12.45 | $10.2 |
| Effect of exchange rate | -$0 | -$0.01 | -$0.01 | -$0.01 |
| Change in cash and equivalents | $0.6 | -$2.41 | $0.71 | $5.13 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.09 | $1.85 | -$0.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $17.57 | $3.13 | $33.3 | $0.43 |
| Effect of exchange rate | $0 | $0.03 | ||
| Change in cash and equivalents | $0.6 | -$18.86 | $19.81 | -$10.15 |
News
Fundamentals
| Market cap | $3.94M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 23.46M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.73 |
| Quick ratio | 1.74 |